Registry and sample resource for patients with plasma cell disorders
Buckeye Surveillance, Contact, and Research for Multiple Myeloma and Amyloidosis
Ohio State University Comprehensive Cancer Center · NCT01408225
This study is gathering information from patients with plasma cell disorders like multiple myeloma to see how to improve their treatment and quality of life.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ohio State University Comprehensive Cancer Center (other) |
| Locations | 1 site (Columbus, Ohio) |
| Trial ID | NCT01408225 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather comprehensive data on patients diagnosed with plasma cell dyscrasias, including multiple myeloma and AL amyloidosis, to enhance their quality of life and longevity. The research involves creating a database that tracks treatment effectiveness, patient experiences, and survival outcomes. Additionally, the study provides patients with access to clinical consultations and information about local support resources. By engaging with patients across Ohio, the investigators hope to develop targeted interventions to reduce morbidity and mortality associated with these conditions.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with plasma cell dyscrasias, such as multiple myeloma or AL amyloidosis.
Not a fit: Patients who are incarcerated will not benefit from this study due to their lack of access to the necessary clinical resources.
Why it matters
Potential benefit: If successful, this initiative could lead to improved treatment strategies and support for patients with plasma cell disorders.
How similar studies have performed: Other studies focusing on patient registries and tissue banking for rare diseases have shown promise in improving patient outcomes and advancing research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion: Diagnosis of a plasma cell dyscrasia Exclusion: Prisoners are excluded from participation as they have no standard access to the Ohio State myeloma clinic and would impede the research objective of this protocol.
Where this trial is running
Columbus, Ohio
- Ohio State University Medical Center — Columbus, Ohio, United States (RECRUITING)
Study contacts
- Principal investigator: Don Benson, MD — Ohio State University
- Study coordinator: The Ohio State University Comprehensive Cancer Center
- Email: OSUCCCClinicaltrials@osumc.edu
- Phone: 1-800-293-5066
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Plasma Cell Dyscrasias, Monoclonal Gammopathy of Undetermined Significance, AL Amyloidosis, Multiple Myeloma, MGUS, Tissue Bank